Don’t recommend Amyloid PET (positron emission tomography) in asymptomatic individuals without cognitive impairment, even in the presence of a familiarity for dementia, and in subjects reporting deficits not confirmed by the neuropsychological evaluation.
Amyloid PET is not a diagnostic test for Alzheimer’s disease but rather an index of cerebral amyloidosis, and may be positive in other forms of dementia (i.e. dementia with Lewy bodies), and in asymptomatic subjects. Furthermore, the accuracy of this exam decreases...
Don’t recommend brain ¹⁸F-FDG PET (positron emission tomography) in the diagnostic investigation of dementia when clinical and neuropsychological assessment, laboratory tests and basic neuroimaging adequately support diagnosis.
FDG-PET imaging investigates brain glucose hypometabolism. When clinical and neuropsychological assessment, laboratory tests and basic neuroimaging adequately support dementia diagnosis and aetiology, further exams provide inconsistent diagnostic benefits. On the...
Don’t use benzodiazepines or other sedative-hypnotics in older adults as first choice for insomnia.
Older adults have increased sensitivity to benzodiazepines and other hypnotics and decreased drug metabolism. In general, all benzodiazepines increase risk of cognitive impairment, delirium, falls, fractures and motor vehicle accidents, leading to hospitalization and...
Don’t use antipsychotics as the first choice to treat behavioral symptoms of dementia, avoiding prescription before careful evaluation and removal of precipitating factors.
People with dementia often exhibit behavioral symptoms such as agitation, aggression, anxiety, irritability, depression, apathy and psychosis. In this context, antipsychotic medicines are often prescribed, but they often provide limited and inconsistent benefits, with...The campaign DOING MORE DOES NOT MEAN DOING BETTER – CHOOSING WISELY ITALY is promoted by Italy’s Slow Medicine
Recent Comments